Clindamycin - ULURU

Drug Profile

Clindamycin - ULURU

Alternative Names: ResiDerm A; Zinc clindamycin; Zindaclin

Latest Information Update: 12 Mar 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ULURU
  • Class Antibacterials; Lincosamides; Small molecules
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acne

Most Recent Events

  • 21 Apr 2011 ProStrakan has been acquired by Kyowa Hakko Kirin
  • 29 Jun 2010 A subsidiary of Crawford Healthcare acquires clindamycin from Strakan and ULURU
  • 18 Dec 2006 Clindamycin licensed to Crawford Healthcare in certain Western European countries, Central Eastern Europe and the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top